timothy sykes logo
Cidara Therapeutics: Unexpected Stock Rally Thumbnail
G Google News

Cidara Therapeutics: Unexpected Stock Rally

MATT MONACO•UPDATED SEP. 24, 2025, 2:33 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Cidara Therapeutics Inc. stocks have been trading up by 21.51 percent after promising FDA designations and positive results.

Key Highlights

  • Analysts anticipate big gains for Cidara Therapeutics, prompted by WBB Securities upgrading its price target from a modest $45 to a staggering $123. The spotlight is on CD388, a promising antiviral project that could change flu treatment.

  • Fresh excitement surrounds positive data from Cidara’s Phase 2b NAVIGATE study, showcasing CD388’s compelling safety and efficacy, alongside encouraging preclinical outcomes against the notorious H5N1 virus.

  • Cidara Therapeutics reveals plans to present two significant oral presentations at the ISRV 2025 meeting, featuring groundbreaking Phase 2b data and H5N1 preclinical results on CD388, amidst anticipation from the Fast Track Designated FDA.

  • Investment discussions heat up as Cidara highlights advancements in its proprietary Cloudbreak platform development during September, indicating significant progress in its flagship CD388 candidate and oncology department, notably with CBO421.

  • Cidara seems to be providing directional clues to investors with robust participation in key September investor conferences to showcase its innovations and development presence in the biotech field.

Candlestick Chart

Live Update At 14:32:31 EST: On Wednesday, September 24, 2025 Cidara Therapeutics Inc. stock [NASDAQ: CDTX] is trending up by 21.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Roundup and Insights

Trading can often seem overwhelming to newcomers, as the market experiences constant fluctuations and the pressure to make profitable decisions can be intense. To navigate these challenges, adopting a disciplined strategy is crucial. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” This approach emphasizes the importance of minimizing losses early on, allowing gains to grow, and avoiding excessive trading that can lead to mistakes. By internalizing these principles, traders can better manage risks and enhance their chances of long-term success.

Cidara has captured investor buzz thanks to fascinating happenings in its recent stock performance, as well as striking financial metrics driving analyst excitement. This biotech firm, focusing on its Cloudbreak platform, has been making bets that could significantly reshape its financial future.

From the CSV data provided, Cidara’s stock leaped from an opening of $77.4 to close at $89.3 on Sep 24, 2025, a telling indicator of market optimism about the company’s prospects. Such a notable climb suggests a growing investor interest most likely tied to the recent favorable news flow around its products and their potential success in the medical landscape.

Examining key financial metrics from recent data, Cidara’s current ratio stands strong at 16.5, affirming its impressive ability to cover current liabilities. However, the company still grapples with profitability, shown by a pre-tax profit margin of -241.1. This significant challenge reflects typical dynamics in biotech as companies invest heavily in research, innovation, and trials before hitting profitable milestones. Nonetheless, a solid balance sheet with total assets valued over $534 million provides a safety net as they navigate these waters.

More Breaking News

From recent financial reports, Cidara generated over $127 million in revenue. A crucial takeaway is a formidable leap in cash flow from $342 million, coupled with a £409 million operating cash challenge—this suggests increasing expenditure likely linked to its aggressive R&D spending. This aligns consistently with Cidara’s strategic bets in the therapeutic arena. While overall retained earnings are in the red, a burgeoning avenue like CD388 could reposition their course dramatically, showcasing how potential innovation impacts investor sentiment.

Stoking Innovation – Impactful Impulses

By presenting its CD388 Phase 2b data at the prestigious ISRV 2025 meeting, Cidara is consciously staking its claim in the medical spotlight. Its inclusion in these high-caliber discussions reinforces its credibility and potential breakout success in antiviral development. Additionally, signaling the FDA’s Fast Track Designation awarded last June, Cidara projects resolute confidence towards swift progression.

Cidara’s proactive engagement in key conferences must not go unnoticed. It signals a company aware of its potential and determined to create a powerful narrative for itself within the investment community. By amplifying the development of CD388 and other promising candidates such as CBO421, Cidara sends a clear message of commitment towards driving value through cutting-edge innovation.

Conclusion: What’s Next for Cidara?

Cidara’s recent news cycle demonstrates significant milestones that bolster its standing in the therapeutic sector. Its stock’s robust uptick highlights the market’s optimistic sentiments towards its antiviral breakthroughs, notably CD388. While current financial metrics show inherent challenges typical of biotech ventures, genuine trader interest could very well fuel and support Cidara’s ambitious blueprints. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades,” advising traders to approach Cidara’s potential with a steady hand.

Financial strategists hunting for strong biotech plays might find Cidara alluring, albeit with the awareness of inherent risks associated with such innovative endeavors. Indeed, garnering FDA attention and following up with stellar trial data success reflects significant growth potential. Traders have reason enough to tune in as Cidara navigates its path forward, cementing its strategy while fostering innovations designed to defy market expectations.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”